By the way cash flow is miserable, and unless I got this wrong there is still 30-40 million in assets, without including AR and intangibles, the debt burden could be short lived and if the capitol burden is available without significant interest burden, and if the the new equity owner buys shares intelligently they would still have a unit price below the stock price after the buyout. Selling these shares would reduce the burden of debt, and the enthusiasm created by this deal would bring the long anticipated attention that this board craves for. Which would drive SP up and create increased assets and operating capital to drive the company forward. These equity firms will have capacity to attract the best and the brightest and certainly will recognize the importance of the recruitment of scientific thought leaders, not just on the "advisory board" but part of management would be essential for success. Look at Regeneron's management team.